Delphine Diagnostics receives Maternal and Infant Health R & D Award Grant from NJ CSIT, New Jersey Commission on Science Innovation and Technology. At Delphine Diagnostics, we are committed to advancing medical diagnostics to improve patient outcomes for pregnant women and infants. Our industry-experienced team is continuously innovating to develop faster and more effective solutions that enhance maternal and infant healthcare. We are deeply honored to receive the Maternal and Infant Health Award on Tuesday, March 5, 2025 and extend our heartfelt gratitude to First Lady Tammy Murphy, NJEDA CEO Tim Sullivan, MIHIA Chair Lisa Asare, and CSIT Executive Director Judith Sheft for their support. This recognition fuels our determination to make pregnancy and childbirth safer, more joyful, and truly sacred experiences for mothers and infants across New Jersey and beyond. Stay tuned as we continue working towards transforming maternal healthcare with cutting-edge diagnostics! #DelphineDiagnostics #MaternalHealth #InfantHealth #HealthcareInnovation #NJEDA #CSIT #MIHIA #MedicalDiagnostics
Delphine Diagnostics Inc
医疗设备制造业
Newark,NJ 272 位关注者
Fast and Accurate Diagnostics for Infectious Diseases
关于我们
Delphine Diagnostics, a New Jersey-based startup, is passionate about delivering top-tier diagnostic products and complementary data insights capabilities to enable speedy treatment for patients impacted by infectious diseases and admitted to hospital settings. As an example of the current status and impact, 350,000 people die due to sepsis-causing infections in the USA every year. As a forward-thinking medical diagnostics enterprise, Delphine Diagnostics aims to manufacture and supply certified testing kits to approved facilities, complemented by advanced artificial intelligence software applications. Our strategy will integrate these intelligent technologies to enhance diagnostic speed and accuracy while adhering to global best practices. This approach elevates the standard of our testing products and positions us at the forefront of technological innovation in healthcare diagnostics. The enterprise team is led by industry-experienced domain and business experts with service and ethical mindsets across biomedical sciences, data analytics, artificial intelligence, and market development. Sepsis Diagnosis Test Kits: As this ground-breaking diagnostic kit nears its development stage, its impact will be far-reaching, promising to revolutionize the field of infection diagnosis and treatment decision support. By expediting accurate diagnosis, tailoring treatments to individual patients, and optimizing antimicrobial usage, this novel technology holds the potential to save lives, improve patient care, and contribute to the global fight against antibiotic resistance. Learn more: https://delphinedx.com/delphine-sepsis-panel-test/
- 网站
-
https://delphinedx.com/
Delphine Diagnostics Inc的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 2-10 人
- 总部
- Newark,NJ
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
211 Warren Street - New Jersey Institute of Innovation - Venture Link Bldg.
US,NJ,Newark,07103
Delphine Diagnostics Inc员工
动态
-
First Lady Tammy Murphy and NJEDA CEO Tim Sullivan Announce CSIT Award of $1.7 Million to 23 Startups Focused on Maternal and Infant Health https://lnkd.in/dHV_3c7b #DelphineDiagnostics #MaternalHealth #InfantHealth #HealthcareInnovation #NJEDA #CSIT #MIHIA #MedicalDiagnostics
-
??? Happy Holidays from Delphine Diagnostics! ??? As we wrap up another incredible year, we want to take a moment to express our heartfelt gratitude to our clients, partners, and supporters. Your trust and collaboration have been instrumental in our journey, and we couldn’t be more thankful. This holiday season, we wish you joy, peace, and meaningful moments with your loved ones. May the new year bring success, growth, and exciting opportunities for all of us! Here’s to a bright and prosperous 2025 together! ???? Warm wishes, The Delphine Diagnostics Team #HappyHolidays #SeasonGreetings #DelphineDiagnostics #ThankYou #HolidaySeason #NewYear2025
-
-
What an inspiring event; we were happy to participate, thanks BioNJ!
? ?Lightning Pitches? ? 90-second intros from trailblazing companies leveraging AI and digital health to revolutionize healthcare. Aixone, Arcade Therapeutics, BioProxal, Delphine Diagnostics Inc, DTxPlus, KolateAI PharmaTech Inc, Live150, Luro Health, Mednovators, Neoneur, Octozi, Quantum BioTek international, Robossis, Serotonix, LLC, Solvuu, Symmetric, Thrive Genetics, Inc., Vasowatch #BioNJAIDigitalHealthDay
-
-
-
-
-
+10
-
-
Thank you to the industry partnership leaders who attended and supported today's amazing event. Your presence was truly appreciated! Komal Dangi Raj Devalapalli Andy Bala Anthony Wallace Daniel Weinstein
-
-
Andy Bala, Delphine DX's Founder and CEO, was?invited to speak?at the Wireless World Research Forum?at Rowan University on June 19th, 2024, as a part of the session for "Advancing Global Communication: The Role of AI in Shaping the Future of Technology", chaired by Professor Nidhal Carla Bouaynaya. The talk titled "The Role of AI in Medical Diagnostics" was very well received. The attendees had several great questions and asked for clarifications regarding scenarios related to false?positive and false negative prediction outcomes of AI-based?models in hospital settings. The presentation also highlighted?the benefits to patient outcomes and reduced hospital stay durations. Thank you to Delphine Team members who contributed to developing this contents. Learn more at: ?? https://wwrf51.wwrf.ch/? ?? https://lnkd.in/ehAd5TtQ #AIinMedicalDiagnostics #WirelessWorldResearchForm
-
-
As a part of the Industry Client Project course at Rutgers Business School, Delphine Diagnostics has been working with talented students looking to make a real-world impact in the Biotechnology and Medical Devices space. It has been great to offer this opportunity for collaboration and to gather valuable and actionable insights. Jesse Chao, PharmD is a pharmacist who has nearly 10 years of experience in the biopharmaceutical industry. He started his career in Pharmacovigilance/Risk Management and eventually transitioned to clinical development. He is currently a clinical scientist at Regeneron Pharmaceuticals working on allergy/immunology drug development. He anticipates completion of the MBA program at Rutgers Business School in August 2024. Emily O'Neill, PharmD, RPh is a pharmacist with five years of experience in the Pharmaceutical Industry. She started her career as a postdoctoral fellow with Rutgers/Bristol Myers Squibb and is now a Cardiovascular Pricing and Access Strategy Lead at Bristol Myers Squibb. Emily is in her final semester of the MBA program at Rutgers Business School. Jaime Rochotte is in the Masters of Supply Chain Analytics Program at Rutgers Business School and has almost 8 years of experience in the logistics industry. She is currently an Inventory Control Analyst at BevDS analyzing inventory levels and recording and reporting the variety pack production done on-site. A big thank you to Professor Joe Agresta for his constant support. Wishing these students the very best of luck and bright futures ahead! #rutgers #rbs #projectmanagement #biotechnology #medicaldevices #diagnostics #collaboration
-
-
In the words of our CEO, Andy Bala: "I'm happy to have attended a valuable event, 'Entrepreneurs Exchange,' at Princeton, New Jersey, last week. I want to share my gratitude for Debbie Hart and her team at BioNJ; a big thank you to Kristin Roosevelt and her Thermo Fisher Scientific team, and Elizabeth Rowley along with her team from Princeton Innovation Center BioLabs.?It was truly a great opportunity to learn and network with fellow entrepreneurs and supporters of Delphine Diagnostics." Follow us to keep up with the latest developments in the diagnostics space. #princetoninnovationcenter #bionj #thermofischerscientific #entrepreneurs
-
-
Delphine Diagnostics is honored to be a presenter at the 14th?BioNJ Bio Partnering Conference held at the Liberty Science Center, Jersey City, NJ. Delphine was one of the firms selected to pitch during the startup pitch competition. The full-day program included nearly 90 pitch presentations from innovative companies across the life science, biotech, healthcare, and digital health sectors. Andy Bala, CEO of Delphine Diagnostics, represented the firm during the pitch competition and connected with Industry Leaders during the well-attended BioNJ Bio Partnering conference. The highly successful bio-partnering conference at the new location was only possible with meticulous planning and flawless execution by Leaders from BioNJ?and Strategic partner organizations. Thanks to Debbie Hart, Pavita Howe, Mahako E., Frances Keel, and Sarah-Beth Vaughn for organizing such a great event. Meeting John F. Coelho, Jim Gunton, Gary Shangold, Mark Kolb, Vince Smeraglia, Rahul Krish, and other accomplished individuals was truly a pleasure. Delphine appreciates BioNJ's?efforts to enable an effective platform for networking at the highly sought-after Industry Connections desk and numerous one-on-one partnering meetings. Stay tuned as Delphine gathers momentum on our journey to save lives by providing top-notch diagnostic products. #BioNJ #BioTech #Diagnostics #Startup #Innovation
-